Amicus Therapeutics (FOLD): $0.9 million was the positive money flow into the stock on Tuesday and the up/down ratio of ticks was also in favor of the bulls at 2.69. The value of trades done on upticks was $1.44 million, whereas, trades done on downticks were valued at $0.54 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.79 million worth stocks on upticks, which is a bullish indication. The downticks accounted only for $0.06 million worth of block trades showing a lack of interest among the large traders to sell the stock down. The up/down ratio of 13.32 was strongly in favor of the bulls. The money flow in block trades was $0.73 million. Amicus Therapeutics (FOLD) fell $0.01 traded at $5.9, a change of -0.17% over the previous day. The stock is -1.67% for the week.
The company Insiders own 8.3% of Amicus Therapeutics shares according to the proxy statements. In an insider trading activity, Rosenberg Ellen, officer (General Counsel & Corp. Secy) of Amicus Therapeutics Inc, executed a transaction worth $115,050 on June 2, 2016. A total of 15,000 shares were purchased at an average price of $7.67. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Shares of Amicus Therapeutics, Inc. appreciated by 7.53% during the last five trading days but lost 0.83% on a 4-week basis. Amicus Therapeutics, Inc. has dropped 24.43% during the last 3-month period . Year-to-Date the stock performance stands at -38.14%.
Amicus Therapeutics (NASDAQ:FOLD): stock turned positive on Tuesday. Though the stock opened at $6.02, the bulls momentum made the stock top out at $6.09 level for the day. The stock recorded a low of $5.9 and closed the trading day at $6, in the green by 1.52%. The total traded volume for the day was 2,385,098. The stock had closed at $5.91 in the previous days trading.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.